Cochlear HY26 Financial Results Show Nexa Rollout Impact
Cochlear Limited posted both positive and negative Cochlear HY26 financial results, with the rollout of the Nexa System creating a...
Neuren Pharmaceuticals Welcomes Reauthorisation of US Priority Review Voucher Program
Neuren Pharmaceuticals Limited (ASX: NEU) has announced that the United States Congress has reauthorised the Rare Pediatric Disease...
Neuren Pharmaceuticals Confirms Daybue Sales Outlook After ASX Aware Letter
Neuren Pharmaceuticals reacted to an ASX aware letter after its Daybue global sales projections announcement, which was of a...
Affordable £2.50 Drug Extends Lives of Prostate Cancer Patients
A prostate cancer drug costing just £2.50 per day will extend the lives of thousands of patients. This generic version of abiraterone...
JPMorgan Healthcare Conference 2026 Breaks Ground On Pharma Frontiers
Sanofi presented its challenges and possibilities at the JPMorgan Healthcare Conference 2026. The company indicated the near-term...
Aged Care Crisis Australia Deepens As Allman-Payne Blasts Health Officials Over System Failures
The aged care crisis that Australia is facing has been greatly intensified after Senator Penny Allman-Payne strongly criticised top health...
Could This Common Drug Stop One of Childhood’s Deadliest Cancers?
Australian researchers have uncovered something remarkable hiding in plain sight. A medication already approved for other uses might hold...
Popular Hair Loss Medication Hides Dark Secret: Men Face Suicide Risk After Treatment
Millions of men worldwide reach for finasteride when thinning hair threatens their confidence. What they don’t expect is a battle...
Medibank’s Bold Vision: Doubling Health Engagement to 10 Million by 2030
Medibank aims to double its health and wellbeing engagement to 10 million Australians by 2030. The company plans to grow its policyholder...
Botanix Pharmaceuticals Sofdra Revenue Surges 65% In Q1 FY26
Botanix Pharmaceuticals Limited (ASX: BOT) has disclosed a spectacular first quarter for FY26 that was aided by a swift Sofdra sales...
